• Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available.
• The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients.
• HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency.

Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective therapies is urgent. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is focused on developing and commercializing products to treat rare diseases. At the forefront of Soligenix’s pipeline is HyBryte(TM), a novel therapy aimed at treating early-stage CTCL.

CTCL affects the skin by causing malignant T-cells to accumulate in the upper layers, often resulting in patches, plaques and tumors that can be intensely itchy, painful, and disfiguring. The disease can significantly impair quality of life and, in more advanced stages, may involve other parts of the body such as the lymph nodes, blood and internal organs.

According to the Cutaneous Lymphoma Foundation, approximately 3,000 new cases of CTCL are diagnosed in the United States each year, with an estimated 30,000 to 40,000 individuals living with the disease nationwide (https://ibn.fm/Rh6HC). While CTCL tends to progress slowly, it is chronic and currently incurable, requiring ongoing treatment to manage symptoms and improve patients’ quality of life.

This chronic nature makes the search for better treatment solutions even more critical, especially as existing therapies often involve systemic immunosuppressants, phototherapy or chemotherapy, which can carry serious side effects and limit long-term effectiveness. The need for treatments that are not only effective but also safe and tolerable over long durations is pressing.

Soligenix’s HyBryte(TM) (synthetic hypericin) is a photodynamic therapy using synthetically manufactured hypericin, which is one of the most photoactive compounds available (https://ibn.fm/6L6oR). Used in ointment or gel form, synthetic hypericin is combined with visible fluorescent or LED light. Because it is easily activated with relatively low-energy light, HyBryte(TM) is ideal for photodynamic therapy because it can be activated with safe visible light instead of damaging UVA or UVB light, which are associated with increased cancer risks.

This mechanism is particularly significant in treating CTCL, a condition that often requires repeated and prolonged skin treatments. HyBryte(TM) offers a noninvasive alternative that may reduce the cumulative toxicity and side effects often seen with current options.

The therapeutic potential of HyBryte(TM) has been demonstrated in multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. The company recently released interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) treatment for up to 54 weeks in patients with early-stage CTCL (https://ibn.fm/N3np8). Following 18 weeks of treatment, 75% of patients achieved “treatment success,” reinforcing HyBryte(TM) as a potentially safe and fast-acting therapy for this chronic and underserved cancer.

In January 2025, Soligenix announced expanded access treatment results that also showed positive outcomes, reinforcing the drug’s safety and efficacy profile in real-world applications (https://ibn.fm/ntbfY). Patients who continued treatment beyond the original trial timeline maintained or improved their clinical responses, a particularly encouraging outcome in the management of a disease known for its relapsing and remitting course.

HyBryte(TM) has also been granted Orphan Drug Designation by the U.S. Food and Drug Administration (“FDA”), which provides regulatory incentives including market exclusivity, tax credits for clinical testing, and exemption from user fees. This designation not only underscores the drug’s potential to address an unmet medical need but also enhances its commercial viability, if approved. Furthermore, Soligenix has expressed intentions to pursue marketing approval worldwide, including the European Union, where HyBryte(TM) has also received Orphan Drug Designation from the European Medicines Agency (“EMA”), which could pave the way for broader access to the treatment and significant benefits for patients globally.

In addition, Soligenix is engaging with the broader medical and scientific communities to ensure HyBryte’s(TM) integration into treatment protocols, should regulatory approval be granted. As the company continues to build on its clinical successes, its commitment to innovation in rare disease treatment remains clear. The development of HyBryte(TM) for CTCL reflects Soligenix’s broader mission: to deliver novel treatment solutions for underserved patient populations. With the increasing prevalence of CTCL and the limited scope of current treatment options, HyBryte(TM) could represent a much-needed breakthrough in how the disease is managed, offering new hope to thousands of individuals living with this complex and chronic lymphoma.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

• The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics.
• HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25.
• Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer.
• NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE’s strategy to establish a scalable mental health treatment network of interventional psychiatry clinics. (https://ibn.fm/DjOMz).

Kadima, located in La Jolla, California, will become the clinical and operational template for the proposed network. Known for its work in interventional psychiatry, the clinic’s integration with HOPE Therapeutics is expected to drive immediate financial gains, including EBITDA growth.

HOPE Therapeutics is targeting the acquisition of up to 30 clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. The company is positioning these clinics to address critical gaps in care for patients experiencing suicidal depression, post-traumatic stress disorder, and other complex mental health conditions.

Dr. David Feifel, founder of Kadima and a recognized figure in interventional psychiatry, will take on the role of Chief Medical Innovation Officer at HOPE Therapeutics. His appointment is viewed as a key asset for the company’s clinical strategy. “Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team,” said HOPE Co-CEOs Dr. Jonathan Javitt and Matthew Duffy. “With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care.”

The acquisition of Kadima is part of a broader expansion by HOPE Therapeutics into the outpatient psychiatric treatment space. Additional agreements are already in place to acquire Dura Medical and a letter of intent has been signed with Neurospa TMS. This expansion reflects growing demand for more accessible, evidence-based interventions in psychiatric care, including ketamine-based treatments and neuromodulation techniques.

Kadima’s offerings include therapies that go beyond conventional medication management, reflecting a rising interest among investors and healthcare providers in new psychiatric modalities.

NRx Pharmaceuticals is concurrently advancing a drug development pipeline focused on central nervous system (“CNS”) disorders. Its lead asset, NRX-101, has received Breakthrough Therapy Designation from the FDA for treatment-resistant bipolar depression with acute suicidality. Another program, NRX-100, a preservative-free IV formulation of ketamine, has Fast Track status and is aimed at acute suicidality treatment.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

• Nightfood Holdings new executives have strong track records in a variety of spaces
• NGTF’s new leadership team is poised to leverage their combined expertise to facilitate the company’s growth and innovation

The foundation of any successful company often rests on the quality and vision of its leadership. Experienced executives can be the deciding factor between stagnation and rapid growth, particularly in dynamic sectors such as consumer goods and hospitality. That’s why Nightfood Holdings (OTCQB: NGTF) made waves recently with its announcement of new senior leadership appointments aimed at accelerating innovation and expansion across its growing portfolio of hospitality-focused services.

According to a McKinsey & Company study, companies in the top quartile for executive team effectiveness were 1.9 times more likely to post above-average profitability than their peers (https://ibn.fm/Bkk51). These types of numbers underscore the tangible impact that proven, visionary leaders can have in steering a company through market complexities, evolving consumer expectations, and scaling operations.

With this context in mind, Nightfood Holdings’ recent announcement is especially compelling. The company has appointed Jimmy Chan as Chief Executive Officer and Ried Floco as president and director (https://ibn.fm/GgEOw). These two executives have strong track records in a variety of spaces, including the hospitality sector, where automation and artificial intelligence are reshaping service. These appointments are part of Nightfood’s broader initiative to integrate robotics into the hospitality industry, aiming to enhance efficiency and customer experience.

“These leadership transitions mark a pivotal moment in Nightfood’s evolution, aligning the company with two seasoned executives whose combined experience in scaling businesses, leveraging automation and operating in public market environments will drive long-term shareholder value and disciplined growth,” the company noted in the announcement. 

Chan brings more than 20 years of entrepreneurial and capital markets expertise across industries including real estate, international trade, healthcare and hospitality supply. “As the founder of CarryOutSupplies.com, he scaled one of the largest custom-printed foodservice packaging providers in North America, serving thousands of hotels and restaurants,” the company noted. 

Chan is a recognized leader in operational optimization, vertical integration and supply distribution. His experience in taking companies public, executing M&A transactions and restructuring businesses for long-term value creation will support Nightfood’s corporate development, capital markets strategy, and execution as a high-growth public enterprise.

With more than three decades of executive leadership across the hospitality sector, Floco has overseen the performance of some 200 hotel properties and $3 billion in asset valuations. He has led operations across top-tier brands, including Marriott, Hilton, Intercontinental and Starwood Hotels. 

“Floco will drive Nightfood’s Robotics-as-a-Service (‘RaaS’) platform deployment across hospitality verticals while simultaneously leading the company’s hotel asset acquisition strategy,” the company stated. “His deep operational insight will ensure that the integration of AI-powered automation with real estate ownership delivers scalable and efficient performance in Nightfood’s expanding portfolio.

Nightfood’s new leadership team is poised to leverage their combined expertise to facilitate the company’s growth and innovation. By focusing on the integration of AI and robotics into hospitality services, Nightfood Holdings is dedicated to solving current industry challenges. The company’s strategic vision includes expanding its reach and establishing NGTF as a leader in hospitality automation.

As Nightfood Holdings embarks on its next growth phase, the addition of industry-proven leaders reflects the company’s ambitions to scale, diversify, and lead in both the consumer wellness and hospitality innovation spaces. With experienced minds guiding its strategic direction, Nightfood is poised to convert vision into measurable value for stakeholders, customers, and partners alike.

For more information, visit the company’s website at NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain
• Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M
• The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine

As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.

Buprenorphine, the next candidate for Aversa, is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder (“OUD”) (https://ibn.fm/eQizg). Like NTRB’s Fentanyl patch, it offers an effective and safer alternative to full opioid agonists and has become a cornerstone in medication-assisted treatment (“MAT”) for OUD.

Clinical research supports buprenorphine’s advantages over other opioid treatments. A 2018 study published by the National Institute of Health found that patients with OUD treated with buprenorphine following a nonfatal opioid overdose are associated with significant reductions in opioid related mortality (https://ibn.fm/PYwdo).

NTRB is building on this momentum with their novel transdermal delivery system for buprenorphine, using its patented Aversa abuse-deterrent technology. Rather than relying on traditional oral films or sublingual tablets, Nutriband’s model involves embedding aversive agents into the patch itself, which deters misuse by producing unpleasant effects if the product is tampered with or consumed orally or intravenously. This innovation is especially important given the high rates of misuse associated with even prescribed opioid therapies.

The company’s Aversa pipeline currently includes two main opioid candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine. AVERSA(TM) Fentanyl, Nutriband’s most advanced product, integrates the deterrent system with an FDA-approved fentanyl patch developed by Kindeva Drug Delivery. According to Nutriband, this would be the world’s first abuse-deterrent fentanyl patch, potentially reducing the risk of diversion, misuse and accidental exposure in a category known for both its efficacy and danger.

AVERSA(TM) Buprenorphine, meanwhile, is being positioned as the next step in the company’s growth. In a market update and based off a Health Advances independent report, Nutriband projected potential peak annual sales of $70 million to $130 million for AVERSA(TM) Buprenorphine in the United States alone upon regulatory approval (https://ibn.fm/foAon). The company is also evaluating international commercialization opportunities, supported by its expanding global patent portfolio.

Nutriband’s broader mission is to develop technologies that reduce the potential for abuse and misuse in pain and addiction treatment. The Aversa platform is designed to be applied to a range of transdermal therapies beyond fentanyl and buprenorphine, potentially addressing multiple categories of prescription misuse. The company believes that its approach could help bridge the gap between effective treatment and public health responsibility in the ongoing fight against opioid-related harm.

As regulators, physicians and patients alike seek new tools to battle the opioid epidemic, Nutriband’s efforts could prove pivotal. If successfully commercialized, Aversa-based products may offer a much-needed blend of efficacy, safety and innovation in a space that has long been fraught with challenges. 

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• Fiscal 2025 marked record revenues of nearly $299 million, with silver production of 6.9 million ounces and 11% year-over-year growth in silver equivalent output.
• The company maintains industry-leading margins with an all-in sustaining cost of $12.12 per ounce of silver over the last 12 months, reinforcing its position as a low-cost producer.
• The company maintains a strong balance sheet with over $369 million in cash and a strategic equity portfolio, ensuring financial flexibility for future growth.
• The company launched construction of its fully funded El Domo copper-gold mine in 2025, with production expected by the end of 2026.
• Silvercorp has published an updated mineral resource estimate for the Condor Project and expects to issue a revised PEA by year-end 2025.
• Silvercorp is committed to strong environmental and social governance practices, holding an MSCI ESG rating of “A” and prioritizing local employment and procurement.

Silvercorp Metals (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

• Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
• GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
• El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
• Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
• Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
• BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
• Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman and CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

For more information, visit the company’s website at https://silvercorpmetals.com.

NOTE TO INVESTORS: The latest news and updates relating to SVM are available in the company’s newsroom at https://ibn.fm/SVM

• NTRB listed on the Nasdaq in 2021, is trading above its IPO price, and hit an all-time high of $11.78 in January of this year
• Nutriband’s AVERSA abuse-deterrent patch technology is FDA-bound and could command a market potential as high as $800 million annually

Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook.

As is typical, the topic of the article focused on Nutriband’s history, technology, and vision. To that point, Nutriband’s core innovation is AVERSA, an abuse-deterrent technology designed to prevent the oral misuse of transdermal patches, particularly fentanyl, which can be 100 times more potent than heroin. The AVERSA system embeds ultra-bitter and ultra-spicy components that, in Melnik’s words, make it “almost impossible for abuse or misuse.” In short, risk of abuse is greatly reduced considering in order to ingest a drug like fentanyl, it will be accompanied by a taste akin to Bitrex meeting Pepper X, a real breakthrough in drug safety.

Adult misuse is one thing, but there is also a very real threat of potential death to children who unknowingly are exposed to residual amounts of fentanyl on patches.

The technology is now patented in more than 45 countries, and Nutriband is partnered with Kindeva Drug Delivery to commercialize new products. The company sees the next major milestone as an FDA submission seeking to bring the product to market.

According to Health Advances, the initial market opportunity for abuse-deterrent fentanyl patches could be between $80–$200 million in the first year of launch. If the FDA mandates such technologies, Melnik estimates the opportunity could swell to $800 million annually. Beyond fentanyl, AVERSA is a platform technology that could be adapted for other pain medications, creating multiple commercial pathways.

Doing It Differently from the Start

Unlike most biotech companies that go public with bloated capital raises, Nutriband went public via a Form 10 filing, handling even the legal work in-house with minimal funds. When bankers offered them tens of millions of dollars early on, Melnik walked away, believing it would ultimately destroy shareholder value. He cites peers who accepted similar terms and are now trading at fractions of their former selves – if they’re still trading at all. Meanwhile, Nutriband continues to trade above its IPO price and even hit an all-time high of $11.78 in January.

Outsmarting the Market and Protecting Shareholders

Melnik spoke candidly about how he witnessed the tactics of Wall Street firsthand. He shared a striking story of how market manipulators seemingly used company news against them. After observing suspicious trading patterns, Nutriband began keeping developments under wraps. In one example, when a patent was quietly announced in late 2021, shares surged from $3 to $10.44 on nearly 150 million shares of volume, the most active stock on Nasdaq that day. The lesson: silence can sometimes protect momentum.

Rather than fight Wall Street games, Melnik and his team took a different route to preserve capital. In 2022, the entire executive team took a 50% pay cut, saving $600,000 and extending their runway by over two years. That financial discipline attracted long-term allies, including a billionaire new investor, who has been very supportive of the company as it nears FDA submission for its flagship product.

Beyond Biotech: Diversified Revenue Streams and Transdermal Expertise

Unlike most early-stage biotech companies, Nutriband generates revenue today. The company operates a manufacturing facility in North Carolina that produces the Active Intelligence tape used by Reebok, among others. They also recently launched a mosquito-repelling patch, now approved for sale in Costa Rica. Melnik and his team personally tested the product by trekking through the Talamanca Mountain range without a single mosquito bite in four days.

Transdermal expertise is Nutriband’s hallmark, and Melnik is as committed as ever. “We only try to control what we can control,” he said. “If Wall Street funds don’t understand that we’re not coming back to them, I don’t know what else will make them.”

Leadership That Puts People First

Melnik isn’t just a President; he’s a founder with skin in the game, having tested products himself and taken financial hits to keep the company alive. Yet when asked in the podcast to share advice with his younger self, he didn’t talk about business plans or capital raises. He spoke about family and time.

His grounded mindset, passion for innovation, and unwillingness to compromise on shareholder value position Nutriband as a rare biotech story, one led by integrity, resilience, and vision that is nearing some critical milestones that could serve as significant catalysts to corporate value.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

MoneyShow, a financial conference and content company that connects experts directly with entrepreneurs and investors, is proud to announce the Mid-Year Portfolio Review Virtual Expo. This online event, scheduled for June 17-18, is an excellent way for attendees to review where markets currently stand and where they are going. It also represents an opportunity for investors and traders to discover timely and practical recommendations that can be implemented right away.

This virtual experience will feature a variety of informative and authoritative speakers, including John Rutledge, Nancy Davis, Avi Gilburt, Jeffrey Hirsch, and Amy Smith. They will discuss mainstream and alternative investments in depth, including stocks, cryptocurrencies, private credit/private equity, precious metals, and real estate. The highly interactive format will also include plenty of time for networking and Q&A.

MoneyShow has built a legacy spanning 44 years, educating individuals passionate about investing and trading at both online and live events. Its strategic and intentional approach has yielded some of the most successful virtual and in-person conferences throughout the years. Both have been lauded for how informative they are and how great a networking opportunity they have proven to be.

The Mid-Year Portfolio Review Expo will be no different. It will be the go-to expo for attendees to learn about the different wealth-building alternatives and how they can boost portfolio performance. It will be a chance for those who sign up to learn about the best plays for the second half of 2025, giving them tremendous leverage over other investors.

Interested persons can get a first-hand look inside the MoneyShow virtual platform. There, they can view videos from previous events and read through live presentations covering everything from market analysis to portfolio recommendations to cutting-edge trading strategies and tools. They can also access a growing collection of educational resources, including a digital briefcase to store what they collect.

Registration for the expo is free and is still open.

To learn more, please visit https://ibn.fm/YN76c

Date: June 26

Location: University of California, Irvine

Sustain Southern California (“Sustain SoCal”) is proud to announce the 12th edition of its premier event, Driving Mobility. This event will focus on sustainable transportation solutions, featuring a professional program and an extensive clean vehicle expo unlike any other on the market today. Scheduled for June 26 at University of California, Irvine’s Beall Applied Innovation, the event will bring together clean tech enthusiasts, investors, and entrepreneurs, presenting an excellent opportunity for networking, learning, and building brands.

Some of the topics to be covered at the event include legislation and incentives, vehicle-to-grid integration, autonomous vehicles, Mobility as a Service (“MAAS”), drone applications, and last-mile delivery efficiency. Key industry players and leaders will lend their knowledge and experience at the event, sharing insights into the industry’s current state and its future direction. With this, attendees are guaranteed to stay ahead of the curve, from emerging technologies to legislation that may shape their work.

Sustain SoCal has, since its inception, been committed to proactively addressing the region’s sustainability, environmental, and infrastructure needs and objectives. It acknowledges that the population, industry, workforce, and tourism of Southern California continue to grow and evolve, and with this growth come various environmental challenges. By coordinating conferences, workshops, and networking events, the organization helps share knowledge and establish connections that impact the economic progress and sustainable future of the area, its residents, businesses, and visitors.

The Driving Mobility 12 event is no different. With its focus on clean energy and transportation, the event provides a platform through which policies can be shaped, ideas can be shared, and change can be implemented to create a better society. Being the 12th edition, Sustain SoCal draws from learnings from previous events, making this the best one yet.

To learn more, please visit https://ibn.fm/v5d8l

• Beeline has surpassed $1 billion in loan originations and achieved 38% year-over-year growth in 2024.
• Beeline’s platform was created for the Gig Economy, to increase qualifications for the 75 million millennials who need a variety of fresh, friendly mortgage options under one roof.
• The company offers a unique tech stack, including AI chatbot Bob, the Hive engine, and BlinkQC, which drives faster and more affordable closings.
• Beeline is strongly positioned in DSCR and investor lending markets through strategic partnerships with platforms like Rabbu and Red Awning.
• The expansion of Beeline Labs and the spinout of MagicBlocks creates new SaaS-based revenue opportunities.
• Beeline’s leadership team brings a combination of public company experience and deep domain expertise in real estate, fintech, and AI.

Beeline Holdings Inc. (NASDAQ: BLNE) is a technology-forward mortgage and title platform leveraging AI, automation, and intuitive user experiences to simplify home financing. Through wholly owned subsidiary Beeline Loans Inc., the company delivers fast and flexible loan solutions for both primary homebuyers and real estate investors. Beeline has built an end-to-end digital lending ecosystem designed to eliminate friction, reduce costs, and dramatically shorten closing timelines.

Since completing its October 2024 merger with Eastside Distilling, Beeline has solidified its position as a next generation fintech mortgage originator. Its core vision centers on digitizing the mortgage journey with tools like AI chatbot Bob, proprietary production engine Hive, and an expanding SaaS product suite. These innovations enable Beeline to close loans in just 14–21 days—less than half the industry average—while achieving a Net Promoter Score above 80, more than four times higher than the sector benchmark.

Beeline’s mission is to make home loans effortless by giving users instant access to rate quotes, approvals, and document uploads—all online, 24/7. Having surpassed $1 billion in cumulative loan originations and achieved 38% year-over-year growth, Beeline is scaling its platform across the U.S. mortgage and real estate investing landscape.

The company is headquartered in Providence, Rhode Island.

Products

Beeline operates a fully digital, AI-enabled loan origination and title ecosystem. Key features include:

• Bob 2.0 – The industry’s first AI mortgage agent, available 24/7/365 to quote rates and pre-approve borrowers; Bob has delivered 6x lead conversion and 8x full application volume compared to traditional loan officers.
• Hive – A task-based processing engine that replaces manual workflows with scalable automation, cutting loan closing times to as little as 14 days.
• BlinkQC – Beeline’s proprietary AI quality control platform that replaces costly third-party reviews.
• Beeline Title – A fully diversified title services unit supporting digital collateral transfer, remote closings, and investor-focused solutions.
• MagicBlocks – A customizable AI sales agent platform developed by Beeline and spun out into its own entity; Beeline retains equity and licensing rights, positioning it to benefit from future growth and deployment of the technology.

The company also provides Debt Service Coverage Ratio (“DSCR”), bank statement, and conventional mortgage products tailored to investors, including short-term rental operators. Strategic partnerships with Rabbu and Red Awning streamline property analysis, financing, and management within a single ecosystem.

Market Opportunity

The U.S. mortgage market is poised for growth in 2025, with total mortgage origination volume expected to increase by 28% to $2.3 trillion, up from $1.79 trillion in 2024. This projection includes a 13% rise in purchase originations to $1.46 trillion.

Within this expanding market, investor lending, particularly through DSCR loans, represents a rapidly growing segment. DSCR loans, which are underwritten based on the income generated by the property rather than the borrower’s personal income, are ideal for real estate investors, particularly those purchasing long-term or short-term rental properties. Beeline has strategically positioned itself in this niche, with over one-third of its volume derived from DSCR products. Through its affiliate referral network and integrations with platforms like Rabbu, the company is actively expanding its market reach in this high-margin category.

Non-agency mortgage issuance, which includes DSCR loans, is projected to reach $160 billion in 2025, a 16% increase from 2024.

Leadership Team

Nick Liuzza, Chief Executive Officer, co-founded Beeline Mortgage LLC in 2019 after selling Linear Title & Closing and Linear Settlement Services to Real Matters. He also previously built New Age Nurses into a national staffing firm. He currently serves as EVP of Real Matters (TSX: REAL).

Jess Kennedy, Chief Operating Officer, is a co-founder of Beeline with 15 years of legal and real estate experience. She previously served as General Counsel and Chief Compliance Officer at Beeline and held roles at Solidifi, LeClairRyan, and Edwards Wildman Palmer LLP, handling complex real estate finance and title transactions.

Chris Moe, Chief Financial Officer, joined Beeline in 2023 with over 40 years of finance and investment banking experience. He has held senior roles at Red Cat Holdings (NASDAQ: RCAT), IRIS Therapeutic Devices, and Yates Electrospace Corporation, bringing deep public company and defense sector expertise.

For more information, visit the company’s website at https://makeabeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to are available in the company’s newsroom at https://ibn.fm/BLNE

• SolarBank has announced it will develop a 6.9 MW Brooklyn solar project, located in Nova Scotia and expected to power approximately 900 homes, under Canada’s first Community Solar Program.
• The initiative supports Nova Scotia’s target of 80% renewable energy by 2030 and net-zero emissions by 2035.
• AI Renewable Fund owns the project; SolarBank serves as developer and builder.
• Construction is scheduled to begin in Spring 2026 and complete by Summer 2026, with total development cost estimated at $13.9 million.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., has announced its role as developer and builder for a 6.9 megawatt (“MW”) Brooklyn Project in Nova Scotia, a community solar initiative set to power around 900 homes. The development is part of Canada’s first Community Solar Program (“CSP”) (https://ibn.fm/01vZx). SolarBank has considerable expertise in community solar development in the United States and it is now deploying that expertise in Canada where there remain significant government support and incentives for renewable energy projects.

The project is owned by AI Renewable Fund, which secured two of the three CSP contracts granted to date, totaling 6.5 MW AC. SolarBank will lead the engineering and construction effort in partnership with local firm Trimac Engineering. The total project cost is estimated at $13.9 million.

The Nova Scotia Community Solar Program is central to the province’s plan to reach 80% renewable energy by 2030 and achieve net-zero emissions by 2035. The program aims to add 100 MW of solar power to the grid, with community-based installations that allow residents and businesses to subscribe and receive credits on their electricity bills. Participants save roughly $0.02 per kilowatt-hour for energy generated, without the need to install their own solar panels.

Community solar projects such as Brooklyn are designed to democratize access to renewable energy. Renters and homeowners who are otherwise unable to deploy solar on their own property can benefit from shared clean energy infrastructure. As the developer, SolarBank will now proceed through the permitting phase and initiate technical work including interconnection studies with Nova Scotia Power Inc.

Construction is expected to begin in Spring 2026, with completion targeted for the summer. The Brooklyn site has a secured lease, enabling SolarBank and its partners to move forward with design and engineering in the coming months. This includes in-depth feasibility studies, finalization of the solar layout, and grid integration assessments.

Richard Lu, President and CEO of SolarBank, commented that the company’s long-standing experience in solar development positioned it well for projects under Nova Scotia’s CSP. “As the project developer, we are excited to work alongside our local partner Trimac Engineering and the province’s dedicated team to help bring clean, affordable energy to communities across Nova Scotia,” Lu said. “With over a decade of proven experience in solar development and operations—including community solar, commercial and industrial installations, and other government-led initiatives—SolarBank brings the expertise needed to the successful implementation of Nova Scotia’s Community Solar projects.”

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to the press release entitled “6.9 MW Brooklyn Project in Development by SolarBank in Nova Scotia” for additional details on the information, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN